Effects of remdesivir on SARS-CoV-2 viral dynamics and mortality in viraemic patients hospitalized for COVID-19.
Journal
The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617
Informations de publication
Date de publication:
06 11 2023
06 11 2023
Historique:
received:
23
04
2023
accepted:
14
09
2023
medline:
10
11
2023
pubmed:
27
9
2023
entrez:
27
9
2023
Statut:
ppublish
Résumé
Studies on the antiviral effects of remdesivir have shown conflicting results. SARS-CoV-2 viraemia could identify patients in whom antiviral treatment may be particularly beneficial. To investigate antiviral effects and clinical outcomes of remdesivir treatment in viraemic patients. Viraemic patients hospitalized for COVID-19 with ratio of arterial oxygen partial pressure to fractional inspired oxygen of ≤300, symptom duration ≤10 days, and estimated glomerular filtration rate ≥30 mL/min were included in a cohort. The rate of serum viral clearance and serum viral load decline, 60 day mortality and in-hospital outcomes were estimated. A subgroup analysis including patients with symptom duration ≤7 days was performed. A total of 318 viraemic patients were included. Thirty-three percent (105/318) received remdesivir. The rate of serum viral clearance [subhazard risk ratio (SHR) 1.4 (95% CI 0.9-2.0), P = 0.11] and serum viral load decline (P = 0.11) were not significantly different between remdesivir-treated patients and controls. However, the rate of serum viral clearance was non-significantly higher [SHR 1.6 (95% CI 1.0-2.7), P = 0.051] and the viral load decline was faster (P = 0.03) in remdesivir-treated patients with symptom duration ≤7 days at admission. The 60 day mortality [HR 1.0 (95% CI 0.6-1.8), P = 0.97] and adverse in-hospital outcomes [OR 1.4 (95% CI 0.8-2.4), P = 0.31] were not significantly different between remdesivir-treated patients and controls. Remdesivir treatment did not significantly change the duration of SARS-CoV-2 viraemia, decline of serum viral load, 60 day mortality or in-hospital adverse outcomes in patients with ≤10 days of symptoms at admission. Remdesivir appeared to reduce the duration of viraemia in a subgroup of patients with ≤7 days of symptoms at admission.
Sections du résumé
BACKGROUND
Studies on the antiviral effects of remdesivir have shown conflicting results. SARS-CoV-2 viraemia could identify patients in whom antiviral treatment may be particularly beneficial.
OBJECTIVES
To investigate antiviral effects and clinical outcomes of remdesivir treatment in viraemic patients.
METHODS
Viraemic patients hospitalized for COVID-19 with ratio of arterial oxygen partial pressure to fractional inspired oxygen of ≤300, symptom duration ≤10 days, and estimated glomerular filtration rate ≥30 mL/min were included in a cohort. The rate of serum viral clearance and serum viral load decline, 60 day mortality and in-hospital outcomes were estimated. A subgroup analysis including patients with symptom duration ≤7 days was performed.
RESULTS
A total of 318 viraemic patients were included. Thirty-three percent (105/318) received remdesivir. The rate of serum viral clearance [subhazard risk ratio (SHR) 1.4 (95% CI 0.9-2.0), P = 0.11] and serum viral load decline (P = 0.11) were not significantly different between remdesivir-treated patients and controls. However, the rate of serum viral clearance was non-significantly higher [SHR 1.6 (95% CI 1.0-2.7), P = 0.051] and the viral load decline was faster (P = 0.03) in remdesivir-treated patients with symptom duration ≤7 days at admission. The 60 day mortality [HR 1.0 (95% CI 0.6-1.8), P = 0.97] and adverse in-hospital outcomes [OR 1.4 (95% CI 0.8-2.4), P = 0.31] were not significantly different between remdesivir-treated patients and controls.
CONCLUSIONS
Remdesivir treatment did not significantly change the duration of SARS-CoV-2 viraemia, decline of serum viral load, 60 day mortality or in-hospital adverse outcomes in patients with ≤10 days of symptoms at admission. Remdesivir appeared to reduce the duration of viraemia in a subgroup of patients with ≤7 days of symptoms at admission.
Identifiants
pubmed: 37757451
pii: 7283037
doi: 10.1093/jac/dkad295
pmc: PMC10631829
doi:
Substances chimiques
remdesivir
3QKI37EEHE
Alanine
OF5P57N2ZX
Antiviral Agents
0
Oxygen
S88TT14065
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2735-2742Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
Références
J Infect Dis. 2022 Dec 13;226(12):2089-2094
pubmed: 35511031
J Infect. 2022 Jun;84(6):834-872
pubmed: 35351541
J Clin Invest. 2021 Jul 1;131(13):
pubmed: 34196300
Nat Commun. 2021 Nov 16;12(1):6612
pubmed: 34785663
J Antimicrob Chemother. 2021 Nov 12;76(12):3296-3302
pubmed: 34473275
BMC Infect Dis. 2022 Nov 22;22(1):879
pubmed: 36418984
Clin Microbiol Infect. 2021 Jun;27(6):917.e1-917.e4
pubmed: 33705849
J Antimicrob Chemother. 2022 Apr 27;77(5):1404-1412
pubmed: 35233617
Science. 2021 Jul 9;373(6551):
pubmed: 34035154
BMJ Open. 2021 Dec 8;11(12):e048337
pubmed: 34880010
N Engl J Med. 2021 Oct 7;385(15):1382-1392
pubmed: 34260849
Lancet Infect Dis. 2022 Feb;22(2):209-221
pubmed: 34534511
J Biol Chem. 2020 May 15;295(20):6785-6797
pubmed: 32284326
Nature. 2020 Sep;585(7824):273-276
pubmed: 32516797
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Diagn Microbiol Infect Dis. 2022 Mar;102(3):115595
pubmed: 34896666
Open Forum Infect Dis. 2022 Sep 11;9(9):ofac463
pubmed: 36185351
Clin Infect Dis. 2021 Nov 2;73(9):e2995-e3001
pubmed: 32856036
Sci Rep. 2022 Nov 16;12(1):19658
pubmed: 36385627
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
N Engl J Med. 2022 Jan 27;386(4):305-315
pubmed: 34937145
N Engl J Med. 2021 Dec 2;385(23):e81
pubmed: 34587383
J Med Virol. 2022 May;94(5):2284-2289
pubmed: 35043405
J Antimicrob Chemother. 2022 Jul 28;77(8):2257-2264
pubmed: 35534369
Clin Infect Dis. 2021 Nov 2;73(9):e2898-e2900
pubmed: 32898242
BMC Infect Dis. 2022 Jun 27;22(1):575
pubmed: 35761219
J Korean Med Sci. 2021 Mar 22;36(11):e83
pubmed: 33754512
Ann Intern Med. 2021 Sep;174(9):1261-1269
pubmed: 34251903
Clin Microbiol Infect. 2021 Jun;27(6):886-891
pubmed: 33631334
Clin Infect Dis. 2022 May 3;74(9):1525-1533
pubmed: 34374761
BMJ. 2020 Oct 22;371:m3939
pubmed: 33093056
JAMA. 2020 Aug 4;324(5):460-470
pubmed: 32492084
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Lancet. 2022 May 21;399(10339):1941-1953
pubmed: 35512728